Summary
Beigene, Ltd. (ONC) reported a significant increase in total revenues for the second quarter of 2024, reaching $929.2 million, a 56% rise compared to the same period last year. This growth was primarily driven by a substantial 107% increase in BRUKINSA sales, totaling $637.4 million globally, with particularly strong performance in the U.S. and Europe. Despite the revenue growth, the company reported a GAAP net loss of $120.4 million for the quarter. The company also highlighted its strategic advancements, including the opening of its new U.S. facility in Hopewell, New Jersey, and progress in its pivotal programs for sonrotoclax and BGB-16673. While the company's operating loss narrowed significantly, it continues to invest heavily in research and development and selling, general, and administrative expenses to support its product pipeline and commercialization efforts. Investors should note the significant decline in collaboration revenue due to the termination of prior agreements, which is more than offset by the robust growth in product revenue. The company's cash position remains strong at $2.6 billion, though it is managing a substantial amount of debt, with over $851 million due within the next 12 months. Beigene appears to be on a positive trajectory with its key product, BRUKINSA, gaining market share and driving substantial revenue growth, but continued investment in R&D and commercial expansion will be crucial for future profitability.
Financial Highlights
49 data points| Revenue | $929.17M |
| Gross Profit | $791.03M |
| R&D Expenses | $454.47M |
| SG&A Expenses | $443.73M |
| Operating Expenses | $898.20M |
| Operating Income | -$107.16M |
| Interest Expense | $13.23M |
| Net Income | -$120.41M |
| EPS (Basic) | $-0.09 |
| EPS (Diluted) | $-0.09 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.36B |
Key Highlights
- 1Total revenues increased by 56% year-over-year to $929.2 million in Q2 2024.
- 2BRUKINSA global sales grew by 107% year-over-year to $637.4 million in Q2 2024.
- 3U.S. BRUKINSA sales grew by 114.4% year-over-year to $479.4 million in Q2 2024.
- 4GAAP net loss for the quarter was $120.4 million, a significant improvement from $381.1 million in Q2 2023.
- 5GAAP loss from operations narrowed to $107.2 million, an improvement from $318.7 million in Q2 2023.
- 6Collaboration revenue decreased by 81% year-over-year to $8.0 million.
- 7The company opened its flagship U.S. facility in Hopewell, New Jersey.